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Regulating Cell Surface Glycosylation
by Small Molecule Control of Enzyme Localization
ments of functional elements (Figure 1A). Most of these
enzymes are type II transmembrane proteins, with a
short amino terminus extending into the cytosol, a hy-
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3 Howard Hughes Medical Institute drophobic transmembrane region spanning the Golgi
membrane, and a large carboxy-terminal catalytic do-University of California, Berkeley
Berkeley, California 94720 main positioned in the lumen of the Golgi [4]. The trans-
membrane region and the catalytic domain are sepa-
rated by the so-called stem region, a region of variable
length and sequence. For many, although certainly not all,Summary
Golgi-resident enzymes, the regions controlling cataly-
sis and localization appear to be modular and separableCell surface carbohydrates mediate interactions be-
at the level of amino acid sequence [3, 4]. The amino-tween the cell and its environment. Glycosyltransfer-
terminal residues comprising the cytoplasmic, transmem-ases responsible for synthesis of cell surface oligo-
brane, and stem (CTS) regions of the enzyme are oftensaccharides are therefore essential administrators of
both necessary and sufficient for localization [7, 8]. Forcellular communication. These enzymes often com-
catalysis, only those amino acids of the C-terminal cata-prise large families. Redundacy of related family mem-
lytic domain (CAT) are required [9]. By taking advantagebers and embryonic lethality both complicate genetic
of the modular nature of Golgi-resident enzymes, wemethods for deconvoluting functions of glycosyltrans-
designed a system in which a small molecule can beferases. We report a chemical method in which the
used to control the activity of a glycosyltransferase cata-activity of an individual glycosyltransferase is con-
lytic domain.trolled by a small molecule. The approach exploits the
We reasoned that a protein that contained only therequirement of Golgi localization, a common feature
localization domain of a glycosyltransferase would beof glycosyltransferase superfamily members. In our
retained at the enzyme’s normal location within the Golgiapproach, the glycosyltransferase is separated into
and have access to the enzyme’s usual substrates, buttwo domains, one that determines localization and one
lack the ability to catalyze the reaction. Conversely, aresponsible for catalysis. Control of enzyme activity
protein that contained only the catalytic domain wouldis achieved using a small molecule to regulate associa-
maintain the ability to catalyze the enzyme’s reaction,tion of the two domains. We used this method to regu-
but would not be retained at a location where it hadlate production of sialyl Lewis x by 1,3-fucosyltrans-
access to the appropriate substrates. Conditions thatferase VII in living cells.
caused these two proteins to associate would result in
the retention of the catalytic domain at the site of the
Introduction localization domain and would reconstitute the enzyme’s
normal activity. To control association of the two protein
Compartmentalization within eukaryotic cells allows for domains, we took advantage of the rapamycin-mediated
the formation of microenvironments containing distinct heterodimerization [10] of FKBP [11] and FRB [12]. This
sets of enzymes and substrates; consequently, enzymes ternary interaction has been used widely to mediate the
only utilize substrates that they can access [1, 2]. No- dimerization of protein fragments [13–15] and provides
where is this more true than in the secretory pathway a mechanism for small molecule control of the associa-
[3–6]. The spatial distribution of glycosyltransferases tion of localization and catalytic domains (Figure 1B).
and sulfotransferases within the Golgi cisternae forms Herein, we demonstrate the strategy as applied to the
an assembly line for glycoprotein and glycolipid biosyn- glycosyltransferase human 1,3-fucosyltransferase VII
thesis. Newly synthesized proteins destined for secretion (FucT7) [16, 17].
or for the plasma membrane traverse the individual com-
partments of the secretory pathway before arriving at
the cell surface. Along the way, proteins become decor- Results and Discussion
ated with complicated carbohydrates in an ordered and
regulated fashion. Changes in localization of individual Engineering FucT7 for Small Molecule Control
Golgi-resident enzymes can result in profound changes FucT7 and another fucosyltransferase with similar activ-
in glycosylation, either by denying enzymes access to ity, FucT4, collaborate in fucosylation of the glycans that
their normal substrates or by allowing them access to mediate leukocyte-endothelial cell interactions in the
uncharacteristic substrates. The observation that local- lymph node and at sites of inflammation [18, 19]. FucT7
ization is a critical determinant of Golgi-resident enzyme installs fucose in an -1,3 linkage to GlcNAc in the sub-
activity suggests regulation of localization as a possible strate sialyl LacNAc, generating sialyl Lewis x (sLex) and
mechanism for controlling that activity. related structures [20]. FucT7 accepts only sialylated
Many of the Golgi-resident enzymes responsible for structures [16, 17]; in order to access the appropriate
glycosylation exhibit similar primary structural arrange- substrates, FucT7 must localize to the Golgi in the same
compartment or a compartment subsequent to that
where sialylation takes place. We relied on previous work*Correspondence: crb@uclink.berkeley.edu
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Figure 1. Design of the Conditional Glycosyl-
ation System for Small Molecule Control of
Golgi Enzyme Activity
(A) Anatomy of a type II membrane-resident
glycosyltransferase. The localization (CTS)
domain is comprised of the cytoplasmic tail
(C), the transmembrane region (T), and the
lumenal stem region (S). The catalytic (CAT)
domain is responsible for performing the gly-
cosyltransfer reaction. Residue numbers cor-
respond to human FucT 7.
(B) Mechanism of small molecule control of
glycosyltransferase activity. In the absence
of rapamycin, the catalytic domain is se-
creted to the exterior of the cell, and little of
its product is observed on the cell surface.
When rapamycin is added, the catalytic do-
main is retained in the Golgi, and the en-
zyme’s normal activity is reconstituted.
(C) Fusion proteins are composed of either
FKBP or FRB linked to either the localization
(CTS) or catalytic (CAT) domain of FucT 7. VH,
the secretion signal derived from the murine
Ig -chain; HA, hemagglutinin peptide epi-
tope tag; myc, myc peptide epitope tag.
to identify the portion of FucT7 necessary and sufficient FKBP-CAT, produced cell surface sLex slightly above
background levels but significantly below that observedfor localization [21] and, similarly, the region that com-
prised a functional catalytic domain [22]. We designed for full-length FucT7. This very low level of activity may
result from catalytic domains passing through the Golgiplasmids encoding the localization and catalytic do-
mains of FucT7 fused to FKBP and FRB (Figure 1C). as they are secreted. Simultaneous transfection with
a localization domain plasmid and a catalytic domainFor localization plasmids, FKBP or FRB was appended
C terminal to amino acids 1–51 of FucT7 (CTS, Figure plasmid resulted in sLex levels similar to those observed
for a catalytic domain alone.1A), generating the plasmids CTS-FKBP and CTS-FRB.
For the catalytic domain plasmids, FKBP or FRB was To test the effect of rapamycin on cells expressing
FucT7 chimeras, cells were split one day after transfec-appended N terminal to amino acids 39–342 of FucT7
(CAT, Figure 1A). These plasmids were designated tion into two populations. One population was incubated
with normal media and one with media containing 200FKBP-CAT and FRB-CAT. The catalytic domain plas-
mids also contained an N-terminal secretion tag derived nM rapamycin. After 18 hr of rapamycin exposure, we
measured cell surface sLex levels and compared the meanfrom the mouse immunoglobulin heavy chain (VH). The
addition of the secretion tag was necessary for the chi- fluorescence of rapamycin-treated cells with the mean
fluorescence of the corresponding untreated cells. Themeric protein to enter the endoplasmic reticulum. Once
in the secretory pathway, the ER signal peptide is cleaved, filled bars in Figure 2A show the mean fluorescence
observed for cells incubated with rapamycin and subse-and the protein, lacking any localization domain, is se-
creted by default to the exterior of the cell. All plasmids quently stained for sLex expression. Cells transfected
with CTS-FRB and FKBP-CAT or with CTS-FKBP andalso encoded epitope tags, either myc or HA, for anti-
body recognition. FRB-CAT were expected to respond to rapamycin. The
populations incubated with rapamycin displayed an in-Plasmids encoding these chimeric proteins, as well
as one encoding wild-type FucT7, were transfected into crease in sLex expression when compared to the popula-
tion incubated in the absence of rapamycin (compareCHO cells. Two days after transfection, cell surfaces
were stained using biotin-conjugated HECA-452 fol- open and filled bars in Figure 2A). We attribute the in-
crease in sLex production to rapamycin-induced dimer-lowed by staining with streptavidin conjugated to the
fluorescent dye Tricolor. HECA-452 recognizes sLex and ization of FRB and FKBP, which thereby retains the CAT
protein at the site of the CTS protein, a location whererelated epitopes; these are absent on wild-type CHO
cells due to a lack of 1,3-fucosyltransferase activity the catalytic domain can encounter appropriate sub-
strates. Rapamycin treatment had no effect on sLex pro-[23]. Binding of HECA-452 has an absolute requirement
for fucosylation. Flow cytometry analysis showed that duction for mock-transfected cells or cells transfected
with the full-length FucT7 gene. Similarly, cells trans-cells transfected with full-length FucT7 displayed high
levels of sLex, as evidenced by their high mean fluores- fected with only a localization domain plasmid or only a
catalytic domain plasmid showed no rapamycin-medi-cence, while mock-transfected cells lack sLex. When
transfected with either of the localization plasmids CTS- ated increase in sLex expression. Importantly, cells trans-
fected with CTS-FKBP and FKBP-CAT or with CTS-FRBFRB or CTS-FKBP, cells displayed only background lev-
els of staining with HECA-452, similar to that observed and FRB-CAT did not respond to rapamycin, consistent
with fact that rapamycin does not induce homodimeriza-on wild-type CHO cells (Figure 2A, open bars). Transfec-
tion with either catalytic domain plasmid, FRB-CAT or tion of FKBP or FRB.
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late transcription or signaling pathways suggested that
multiple FRB or FKBP domains might enhance the rapa-
mycin response [24, 25]. We explored a similar strategy
to increase the rapamycin-dependent FucT7 activity in
our system, with the aim of achieving rapamycin-induced
activity comparable to that of full-length FucT7. A series
of plasmids was produced in which the FRB or FKBP
domains were repeated two or three times (3XFRB-CAT
in Figure 1C is an example). These plasmids were trans-
fected pairwise into CHO cells and assayed for rapa-
mycin-induced changes in expression of sLex. For all
cognate plasmid pairs, cells incubated in the presence
of rapamycin displayed sLex expression greater than or
equal to equivalent cells incubated without rapamycin
(data not shown). The strongest rapamycin response
was observed for cells transfected with plasmids encod-
ing two or three copies of FRB linked to the catalytic
domain. The plasmid pair CTS-FKBP and 3XFRB-CAT
showed the largest increase in sLex expression in re-
sponse to rapamycin and was used for subsequent ex-
periments.
Comparison of Rapamycin-Inducible
and Wild-Type FucT7 Activities
Our goal was to develop a system in which the presence
or absence of a small molecule yielded a change in cell
surface glycosylation equivalent to that observed in the
presence or absence of the glycosyltransferase gene.
To assess the ability of our conditional glycosylation
system to achieve this objective, we quantified the rapa-
mycin-induced sLex expression of cells transfected with
CTS-FKBP and 3XFRB-CAT and compared it to the
change in sLex expression that resulted from transfect-
ing cells with full-length FucT7. The histogram in Figure
2B shows the difference in sLex expression between
CHO cells that were mock transfected and those that
were transfected with FucT7. This can be compared to
the histogram in Figure 2C that shows the sLex expres-
sion for cells transfected with CTS-FKBP and 3XFRB-
CAT and treated with 0 or 200 nM rapamycin. On a
qualitative level, the conditional glycosylation system
succeeds, yielding very low levels of sLex in the absenceFigure 2. Rapamycin Increases Cell Surface Expression of sLex
of rapamycin and, upon addition of rapamycin, produc-(A) Cells were transfected with the indicated plasmids, then treated
ing a population of cells expressing high levels of sLex,with 0 (open bars) or 200 nM (filled bars) rapamycin. The mean
comparable to levels produced by cells expressingfluorescence of all live cells was quantified by flow cytometry.
(B–D) Comparison of the activity of the wild-type FucT 7 gene and FucT7. These data are quantified in Figure 2D, which
the small molecule-controlled system. (B) shows a histogram pre- shows that the mean fluorescence associated with rapa-
sentation of flow cytometry data. Fluorescence intensity measures mycin-induced sLex expression is about a third of that
sLex expression on mock transfected cells (black line) and cells
observed by introduction of the FucT7 gene. The inabil-transiently transfected with FucT 7 (red line). (C) shows a histogram
ity of our system to quantitatively reproduce wild-typepresentation of flow cytometry data. Fluorescence intensity mea-
sures sLex expression on cells transfected with CTS-FKBP and FucT7 activity may result from the transient transfection
3XFRB-CAT and treated with 0 (black line) or 200 nM rapamycin conditions, in which some cells are likely to receive
(red line). (D) shows a quantitative comparison of the data shown nonoptimal ratios of the two (CTS-FKBP and 3XFRB-
in (B) and (C). Cells were transfected with the indicated plasmids,
CAT) plasmids.then treated with 0 (open bars) or 200 nM (filled bars) rapamycin.
The mean fluorescence is the average fluorescence of all live cells.
FucT7 Activity Depends on the
FRB-Rapamycin-FKBP InteractionMultiple Copies of FRB Improve
We measured how enhanced expression of sLex de-the Rapamycin Response
pends on rapamycin concentration. The mean fluores-The results of previous studies that used the rapamycin-
mediated interaction between FRB and FKBP to regu- cence of rapamycin-treated cells is plotted versus rapa-
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Figure 4. Time Course of the Rapamycin Response
CTS-FKBP/3XFRB-CAT-transfected cells were stained for sLex ex-
pression after being treated with 0 (closed circles) or 200 nM (open
squares) rapamycin for the indicated period of time. The solid lines
show the best fit of each data set to a single exponential.
were transfected with CTS-FKBP and 3XFRB-CAT, then
treated with 1 nM rapamycin and various concentrations
of ascomycin. These cells were probed for sLex expres-
sion, and the mean fluorescence was plotted versus
ascomycin concentration (Figure 3B). Ascomycin showed
concentration-dependent competition, with half-maxi-
mal signal occurring at about 200 nM. Ascomycin was
Figure 3. Rapamycin Dimerizes FKBP and FRB also able to compete away the rapamycin-dependent
(A) Cells were transfected with CTS-FKBP and 3XFRB-CAT (closed fluorescence change observed for CTS-FKBP/FRB-CAT
circles) or with CTS-FRB and 3XFRB-CAT (open circles). They were transfected cells (data not shown).
treated with various rapamycin concentrations, then stained for sLex We performed a time course experiment to assess
expression. The mean fluorescence of rapamycin-treated cells is
the ability of rapamycin treatment to provide temporalplotted versus rapamycin concentration.
control over FucT7 activity. Cells transfected with CTS-(B) CTS-FKBP/3XFRB-CAT-transfected cells were incubated with
FKBP and 3XFRB-CAT were treated with media con-1 nM rapamycin and the indicated concentration of ascomycin,
then stained for cell surface sLex. The mean fluorescence of the taining 0 nM or 200 nM rapamycin for various times and
ascomycin- and rapamycin-treated cells is plotted versus asco- then analyzed by flow cytometry for sLex expression. A
mycin concentration. measurable increase in sLex expression was observed
for cells that had been exposed to rapamycin for time
periods as short as 1 hr (Figure 4). Subsequent to amycin concentration in Figure 3A. For cells expressing
short (about 0.5 hr) lag time, the rate of increase in sLexCTS-FKBP and 3XFRB-CAT, the mean fluorescence was
expression was fit well by a single exponential with half-dependent on the rapamycin concentration, with half-
maximal signal observed at about 5 hr. Cells that weremaximal stimulation occurring at about 600 pM rapa-
not exposed to rapamycin displayed no time-dependentmycin. As expected, at no concentration of rapamycin
change in sLex expression.did cells transfected with CTS-FRB and 3XFRB-CAT show
detectable expression of sLex. Similarly, cells trans-
fected with CTS-FKBP and FRB-CAT showed an increase Localization of the Catalytic Domain Is Controlled
by Rapamycinin sLex production that was dependent on rapamycin
concentration, while cells transfected with CTS-FRB We took advantage of the HA epitope tag encoded in
the catalytic domain plasmids to confirm that the rapa-and FRB-CAT did not show increased sLex production
at any rapamycin concentration (data not shown). mycin-induced change in FucT7 activity is due to a
change in the physical location of the catalytic domain.To provide further support that the observed changes
in expression of sLex were mediated by dimerization of Cells were transfected with CTS-FKBP and 3XFRB-CAT,
then split into two populations, one of which was treatedFRB and FKBP, we tested the ability of the small mole-
cule ascomycin to abrogate the rapamycin-induced in- with rapamycin. Cells were stained with HECA-452 to
quantify sLex expression, then fixed, permeabilized, andcrease in FucT7 activity. Ascomycin competes with ra-
pamycin for the same binding pocket of FKBP but does stained intracellularly with a FITC-conjugated anti-HA
antibody. Cells treated with rapamycin showed highernot mediate the interaction of FKBP and FRB [26]. Cells
Small Molecule Control of Glycosylation
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Figure 5. Rapamycin Causes the HA-Tagged
3XFRB-CAT to Be Retained Intracellularly
(A and B) Flow cytometry plots showing anti-
sLex staining versus anti-HA staining for cells
transfected with CTS-FKBP and 3XFRB-CAT,
then treated with 0 (A) or 200 nM (B) rapa-
mycin. Numbers inside the plots indicate the
percent of cells found in each quadrant.
(C and D) Fluorescence microscopy of cells
transfected with CTS-FKBP and 3XFRB-CAT,
then treated with 0 (C) or 1 M (D) rapamycin.
Cells were probed with mouse anti-HA fol-
lowed by FITC-labeled goat anti-mouse an-
tibody.
(E–G) Cells treated with 1 M rapamycin and
probed with antibodies against HA and man-
nosidase II. The panels show single sections
of a deconvolved data set. (E), the signal from
mannosidase II staining shown in mono-
chrome; (F), the signal from HA staining
shown in monochrome; (G), three-color over-
lay with mannosidase II staining shown in
green, HA staining in red, and nuclear DAPI
staining shown in blue. Overlap between
mannosidase II and HA staining appears yel-
low in this image.
levels of anti-HA antibody staining (compare Figures with staining for a medial Golgi marker protein, mannosi-
dase II (Figures 5E–5G).5A and 5B), suggesting that more catalytic domain is
retained in these cells. Furthermore, there was a sub- In summary, we present a system in which the activity
of a Golgi-resident enzyme has been engineered forstantial increase in the fraction of cells that were positive
for both sLex and the HA tag, indicating that increased regulation by a small molecule. Due to the similar domain
architecture of most Golgi-resident enzymes, we expectexpression of sLex structures is correlated with an in-
crease in intracellular catalytic domain levels. the conditional glycosylation approach to be readily
extended to the control of other glycosyltransferasesThe rapamycin-inducible production of sLex indicates
that the small molecule causes the catalytic domain and sulfotransferases. In the case described here, rapa-
mycin regulates production of sLex, a critical mediatorto accumulate in the appropriate cellular compartment,
where sialylated substrates are present. This suggests of cell-cell communication. Furthermore, since the level
of sLex expression depends on rapamycin concentra-that the catalytic domain is accumulating in FucT7’s
normal subcellular location, the Golgi. We used immuno- tion, this system has the potential to allow for production
of cells bearing controlled levels of cell surface glycansfluorescence microscopy to verify the localization of the
catalytic domain. Cells were transfected with CTS-FKBP of interest. Such cells could be utilized in biological
assays to probe the relationship between glycan expres-and 3XFRB-CAT, then split, and half were treated with
rapamycin. Both rapamycin-treated and -untreated cells sion levels and function. For example, cells bearing vari-
ous levels of sLex could be tested in a cell rolling assay,were incubated with cycloheximide directly prior to fix-
ing in order to clear the secretory pathway of catalytic which provides a model of leukocyte adhesion to endo-
thelial cells at sites of inflammation, to determine thedomain transiently present during trafficking to the exte-
rior of the cell. Cells were permeabilized and probed critical density of sLex necesssary for recruitment of
cells under conditions of shear stress.with anti-HA antibody, then visualized by fluorescence
microscopy. Due to the transient transfection condi- In addition, the small molecule method provides tem-
poral control over glycan production. It is notable that,tions, not all cells produce the catalytic domain protein,
and those that do produce it vary in expression levels. in this system, control is at the level of protein activity
rather than of RNA or protein production. For this reason,Nonetheless, clear differences were apparent between
those cells treated with rapamycin and those untreated we expect the conditional glycosylation system to pres-
ent a kinetic advantage over systems where small mole-(compare Figure 5C and 5D). The immunofluorescence
experiments show that more catalytic domain is present cule control of gene activity is achieved by regulation
of transcription (such as tetracycline [27, 28], ecdysonein rapamycin-treated cells. Moreover, for cells treated
with rapamycin, the majority of the HA staining overlaps [29], mifepristone [30], rapamycin [25], dexamethasone
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[31], streptogramin [32], or 3-oxo-C8-HSL [33]-inducible gene knockouts have been instructive in determining
the biological targets and functions of individual en-systems) or translation (such as Hoechst dye 33258 [34],
rapamycin [35], or tetracycline [36]-controlled systems). zymes, but lethality and compensation by upregulated
relatives have limited this approach.Although we have not yet compared our system to any
of these others, we expect that deferring control of gly- Chemical tools can overcome limitations associated
with genetic methods [45, 46]. Small molecule “switches”cosylation to a late step in the biosynthetic pathway
will allow for a relatively rapid response to rapamycin. offer temporal control and reversibility and can be
applied to cells and organisms for which the corre-Furthermore, in our system, turning “off” the activity of
the glycosyltransferase requires withdrawal of rapamycin sponding gene knockout would be lethal. For glycobi-
ologists, chemical approaches have amplified impor-and disassembly of the FKBP-rapamycin-FRB complex;
unlike other systems, degradation of the target protein tance, since polysaccharides are not primary gene
products and are therefore difficult to perturb usingmay not be necessary.
Traditionally, small molecule control of enzymes is conventional genetic methods. Yet, there is a relative
dearth of chemical tools with which to modulate thepursued through active-site inhibitors. However, Golgi-
resident enzymes often comprise large families in which synthesis of glycans. A general strategy for controlling
activities of specific glycosyltransferases with smallmembers recognize polar, charged substrates and have
similar active sites; therefore, cell permeability and molecules could accelerate efforts to understand the
functions of glycans.specificity of inhibitors are difficult to achieve. Since
different members of these families seem to have dis- Our strategy exploits the one commonality shared
by many members of the glycosyltransferase family:tinct developmental roles [37, 38], both specific and
temporal control of enzyme activity will be necessary their requirement of Golgi localization for cellular ac-
tivity. We applied the “chemical inducer of dimeri-to deconvolute their activities. If a “knocked-out” gly-
cosyltransferase gene were replaced with rapamycin- zation” strategy [13–15] to control the association of
a glycosyltransferase catalytic domain with its Golgiinducible chimeras analogous to the ones described
here, conditional glycosylation might find application in localization domain and thereby regulate the enzyme’s
activity. Because the approach exploits the commonresolving the in vivo function of individual members of
Golgi-resident enzyme families. If this strategy is suc- domain structure of the glycosyltransferase family
rather than a specific feature of a particular enzyme’scessfully applied in vivo, an added benefit could be
circumvention of the problem of embryonic lethality as- active site, it can be generalized readily to other family
members.sociated with some glycosyltransferase knockouts. We
envision a system in which administration of a small
Experimental Proceduresmolecule activates essential glycosyltransferases dur-
ing early developmental stages, and the targeted en-
Reagentszymes are later inactivated by withdrawal of the drug.
DNA primers were purchased from Sigma-Genosys. The plasmids
In this way, one could study glycosyltransferase knock- pcDNA3.1-Zeo and pCMV/myc/ER were purchased from Invitrogen.
outs at previously inaccessible developmental stages. Restriction enzymes and T4 DNA ligase were from New England
BioLabs. Calf intestinal alkaline phosphatase (CIAP) was from Amer-While the implementation of this system in vivo to by-
sham. Pfu polymerase from Stratagene was used for all PCRs. DNApass embryonic lethality is currently only a theoretical
sequencing was performed by Davis Sequencing, LLC (Davis, CA).possibility, the successful use of rapamycin and its ana-
Rapamycin and ascomycin were purchased from Calbiochem. Ra-logs to control transcription in animal experiments [25,
pamycin was dissolved in ethanol to yield a 1 mM stock concentra-
39–41] suggests that this vision may be achievable. In tion and stored at 20C, and ascomycin was dissolved in dimethyl
vivo experiments may be facilitated by the use of rapa- sulfoxide to yield a 1 mM stock concentration and stored at 20C.
mycin analogs that bind to mutant versions of FKBP
and/or FRB and not to the endogenous proteins [42–44]; Plasmid Construction
Localization Domain Plasmidsorthogonal small molecule-protein pairs should allow
The CTS region of human FucT 7 [16, 17] (GenBank accession num-for small molecule control of glycosyltransferase activity
ber Q11130) was amplified from the plasmid pcDNA3.1()FucT 7 (awithout causing the immunosuppressive effects that are
gift from Steven Rosen, UCSF) by PCR using primers CTS_5 (5-
associated with rapamycin use. TGGCTAGCGTTTAAACGGGCCC-3) and CTS_3 (5-TCTCTAGA
GACAAGGATGGTGATCG-3), then digested with XbaI to yield a
fragment coding for the first 51 amino acids of FucT 7. This fragment
was ligated into the plasmid pcDNA3.1-Zeo, which had been di-Significance
gested with Nhe I and Xba I and treated with CIAP. The identity of
the product, pcDNA3.1-CTS, was verified by sequencing.We present a general strategy for controlling the cellu-
A PCR product encoding FKBP-myc was produced using DNAlar activity of glycosyltransferases using small mole-
encoding human FKBP12 [11] (GenBank accession number
cules. Glycoconjugates, the products of glycosyltrans- 1613455A) as a template (a gift from David Austin and Fei Liu, Yale
ferases, mediate cell-cell interactions fundamental to University) and FKBP_5 (5-ACTCTAGAATCCTCTGGCATGAGAT
GTGG-3) and FKBPmycstop_3 (5-TCACTAGTCTACAGATCCTCTorgan development, cell trafficking, learning and mem-
TCTGAGATGAGTTTTTGTTCTTCCAGTTTTAGAAGCTCC-3) as prim-ory, and the immune response; glycosyltransferases
ers. The PCR product was cloned into the plasmid pCR4Blunt-TOPOare therefore key regulators of complex biological
using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen) to generateprocesses. They comprise a superfamily numbering
TOPO-FKBP-myc, whose identity was confirmed by sequencing.
around 250 in humans, and there is considerable bio- The insert, containing amino acids 2–108 of FKBP12 followed by
chemical redundancy within subfamilies (such as fuco- the myc epitope tag and a stop codon, was excised with XbaI and
SpeI. FKBP-myc was ligated into plasmid pcDNA3.1-CTS that hadsyltansferases, sialyltransferases, etc.). In some cases,
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been digested with XbaI and treated with CIAP, yielding the plasmid FRB_3 (sequences shown above). The PCR product was cloned
into the plasmid pCR4Blunt-TOPO, sequenced, and excised usingCTS-FKBP. The orientation of the insert was confirmed by restriction
digest. Thus, the chimeric gene encoded by CTS-FKBP consists of the restriction enzymes XbaI and SpeI. The FRB insert was ligated
into pcDNA-Vh-CAT that had been digested with XbaI and CIAPamino acids 1–51 of FucT 7, followed by amino acids Ser, Arg (a
vestige of the cloning process), followed by amino acids 2–108 of treated. The resulting plasmid, 1XFRB-CAT, was digested with XbaI,
CIAP treated, and ligated with the FRB insert. The plasmid resultingFKBP, and concluding with the myc epitope tag (EQKLISEEDL).
FRB-myc was produced by PCR using the Marathon human from this ligation, 2XFRB-CAT, was digested with XbaI, CIAP
treated, and ligated with the HA-FRB insert (described above). Thefetal brain cDNA library (catalog #1702-1, Clontech) as a template
and FRB_5 (5-ACTCTAGAATCCTCTGGCATGAGATGTGG-3) and final product, the plasmid 3XFRB-CAT, encodes the murine VH chain
signal peptide, followed by the HA epitope tag, followed by threeFRBmycstop_3 (5-AGACTAGTCTACAGATCCTCTTCTGAGATGAG
TTTTTGTTCCTTTGAGATTCGTCGGAAC-3) as primers. The PCR copies of the FRB domain (amino acids 2021–2113 of human FRAP;
the first copy includes the T2098L mutation) each followed withproduct was cloned into the plasmid pCR4Blunt-TOPO using the
Zero Blunt TOPO PCR Cloning Kit to generate TOPO-FRB-myc, amino acids Ser, Arg (resulting from the cloning process), and con-
cluding with amino acids 39–342 of human FucT 7. The orientationswhose identity was confirmed by sequencing. A point mutation of
FRB, T2098L, that allows binding to rapamycin analogs not dis- of all inserts were confirmed by restriction digests.
cussed here was introduced into this plasmid using the Quikchange
method (Stratagene). Primers used were T2098L_top (5-GGAATGT Flow Cytometry Experiments
CAAGGACCTCCTCCAAGCCTGGGACCTC-3) and T2098L_bottom Chinese hamster ovary (CHO-K1) cells were cultured in F12 nutrient
(5-GAGGTCCCAGGCTTGGAGGAGGTCCTTGACATTCC-3). The FRB mixture (Ham) with L-glutamine (Gibco) containing 10% fetal bovine
insert, containing amino acids 2021–2113 of FRAP [12] (GenBank serum (Hyclone), 100 units/ml penicillin, and 0.1 mg/ml streptomy-
accession number AAA58486) followed by the myc epitope tag and cin. Cell cultures were maintained in a water saturated, 5% CO2
a stop codon, was excised with XbaI and SpeI. FRB-myc was ligated atmosphere at 37C.
into plasmid pcDNA3.1-CTS that had been digested with XbaI and One day prior to transfection, CHO cells were seeded at a density
treated with CIAP, yielding the plasmid CTS-FRB. The orientation of 5  105 cells per well of a 6-well plate (10 cm2 surface area/well).
of the insert was confirmed by restriction digest. Thus, the chimeric For transfection, LipofectAMINE PLUS Reagent (Gibco–BRL) was
gene encoded by CTS-FRB consists of amino acids 1–51 of FucT 7, used according to the manufacturer’s directions, using unsupple-
followed by amino acids Ser, Arg (a vestige of the cloning process), mented OptiMEM I (Gibco) as media during the transfection. One
followed by amino acids 2021–2113 of human FRAP (including the day after transfection, cells were removed from the plate by trypsin-
T2098L mutation), and concluding with the myc epitope tag. ization, counted, and reseeded at a density of 1  105 cells per well
Catalytic Domain Plasmids of a 12-well plate (4 cm2 surface area/well). Cells were incubated for
The plasmid pCMV/myc/ER was digested with NdeI and XhoI to 18 hr in media containing the indicated concentrations of ascomycin
yield a fragment that contains the murine VH chain signal peptide. and/or rapamycin. Three wells were prepared for each ascomycin/
This fragment was ligated into pcDNA3.1-Zeo that had been di- rapamycin concentration to allow the data to be collected in trip-
gested with NdeI and XhoI and treated with CIAP. The resulting licate.
plasmid was designated pcDNA3.1-Vh. The catalytic domain of To remove the cells from the plate for flow cytometry analysis,
FucT 7 (amino acids 39–342) was PCR amplified from pcDNA3.1 they were washed twice with Dulbecco’s phosphate buffered Saline
()FucT 7 using the primers CAT_5 (5-AGTCTAGAGGTACCCCGG (1 PBS, Gibco), then incubated with 1 PBS containing 1 mM
CACCCC-3) and CAT_3 (5-ATACTAGTTCAGGCCTGAAACCAACC- EDTA (0.2 ml/well) for 20 min at 37C. Cells were maintained at 4C
3). The PCR product was cloned into the plasmid pCR4Blunt-TOPO for all subsequent steps. The cells were then washed twice with
using the Zero Blunt TOPO PCR Cloning Kit to generate TOPO- FACS buffer (1 PBS, 1 mg/ml BSA, 0.2% NaN3). Each sample wasCAT, whose identity was confirmed by sequencing. The insert was
incubated in 50 l of FACS buffer containing 2 l of biotinylated
excised with XbaI and SpeI, then ligated into pcDNA3.1-Vh that had
HECA-452 (BD Pharmingen) for 1 hr. The cells were washed twice
been digested with XbaI and CIAP treated. The orientation of the
with FACS buffer, then stained with the secondary reagent, 1 l of
insert was confirmed by restriction digest. The product was termed
tricolor-streptavidin conjugate (Caltag Laboratories) in 50l of FACS
pcDNA3.1-Vh-CAT.
buffer, for 0.5 hr. Following two more washes with FACS buffer, the
The inserts encoding HA-FRB and HA-FKBP were produced in a
cells were resuspended in 150 l of FACS buffer, and the fluores-
fashion analogous to the production of FRB-myc and FKBP-myc
cence of at least 10,000 live cells per sample was measured on the(see above). In this case, the primers used were HAFRB_5 (5-
FL3 channel of a FACSCalibur flow cytometer (BD Biosciences). TheACTCTAGATATCCGTACGACGTACCAGACTACGCAATCCTCTGGC
mean fluorescence intensity was quantified for all live cells.ATGAGATGTGG-3) and FRB_3 (5-AGACTAGTCTTTGAGATTCGT
To assess the time course of sLex expression, 4.5  106 cellsCGGAAC-3) and HAFKBP5 (5-ACTCTAGATATCCGTACGACGT
were transfected with CTS-FKBP and 3XFRB-CAT. One day afterACCAGACTACGCAGGAGTGCAGGTGGAAACC-3) and FKBP_3 (5-
transfection, cells were seeded into 60 wells (1  105 cells per well)TCACTAGTTTCCAGTTTTAGAAGCTCC-3). The inserts were cloned
of 12-well plates. At 0.5 or 1 hr intervals, the media on two wellsinto the plasmid pCR4Blunt-TOPO, sequenced, and excised using
was replaced: one well with plain media and one with media con-the restriction enzymes XbaI and SpeI. The plasmid pcDNA3.1-Vh-
taining 200 nM rapamycin. After 25 hr, the cells were removed fromCAT was digested with XbaI and treated with CIAP. The linearized
the plates and probed for sLex expression, as above.plasmid was ligated with the insert HA-FRB to generate the plasmid
For intracellular staining of the HA-tagged catalytic domain, theFRB-CAT or ligated with the insert HA-FKBP to generate the plasmid
Cytofix/Cytoperm Kit (BD Biosciences) was used. Cells were firstFKBP-CAT. The orientations of the inserts were confirmed by restric-
stained for sLex expression using biotinylated HECA-452 and tri-tion digest. Hence, the chimeric gene encoded by the plasmid FRB-
color-streptavidin, as above. Cells were then fixed by incubating forCAT consists of the murine VH chain signal peptide, followed by the
20 min at 4C in 200 l of BD Cytofix/CytoPerm solution per well.HA epitope tag (YPYDVPDYA), followed by amino acids 2021–2113
Cells were washed twice with BD Perm/Wash buffer, then stainedof human FRAP (including the T2098L mutation), amino acids Ser,
with 2 l of FITC-labeled anti-HA (Covance Research Products,Arg (resulting from the cloning process), and concluding with amino
Denver, PA) in 50 l of BD Perm/Wash buffer for 30 min at 4C. Afteracids 39–342 of human FucT 7. Similarly, the gene encoded by
two washes with BD Perm/Wash buffer, cells were resuspended inFKBP-CAT is composed of the murine VH chain signal peptide, fol-
400 l of FACS Buffer. Fluorescence of at least 10,000 live cells perlowed by the HA epitope tag, amino acids 2–108 of FKBP, amino
sample was measured on the FL1 and FL3 channels of the flowacids Ser, Arg (resulting from the cloning process), and ending with
cytometer.amino acids 39–342 of human FucT 7.
Production of the Plasmid 3XFRB-CAT
Immunofluorescence MicroscopyA series of plasmids were produced containing multiple repeats of
Cells were transfected with CTS-FKBP and 3XFRB-CAT, as above.FRB or FKBP. The construction of 3XFRB-CAT is described here;
One day after transfection, they were seeded (1  105 cells per well)other plasmids were produced in an analogous manner. The DNA
encoding FRB was amplified by PCR using the primers FRB_5 and into two wells of a Labtek II Chamber slide (Nalge Nunc Incorpo-
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rated). One well was incubated with plain media and one with media 7. Yang, W., Pepperkok, R., Bender, P., Kreis, T.E., and Storrie,
B. (1996). Modification of the cytoplasmic domain affects thecontaining 1 M rapamycin. After 2 days, 10 g/ml cycloheximide
(Sigma-Aldrich) was added to both wells for 3 hr. The cells were subcellular localization of Golgi glycosyltransferases. Eur. J.
Cell Biol. 71, 53–61.washed two times with 1 PBS, then fixed with 3% paraformalde-
hyde in PBS for 20 min. Cells were washed three times with 1 8. Milland, J., Russell, S.M., Dodson, H.C., McKenzie, I.F.C., and
Sandrin, M.S. (2002). The cytoplasmic tail of 1,3-galactosyl-PBS, then blocked 15 min with 1 PBS containing 2% BSA. After
permeabilizing for 5 min with 0.1% Triton X-100 in PBS containing transferase inhibits Golgi localization of the full-length enzyme.
J. Biol. Chem. 277, 10374–10378.2% BSA, cells were stained overnight with the primary antibody,
mouse anti-HA (1-1000 dilution, Covance Research Products), in 9. Xu, Z., Vo, L., and Macher, B.A. (1996). Structure function analy-
sis of human 1,3-fucosyltransferase. J. Biol. Chem. 271, 8818–1 PBS containing 2% BSA. Cells were washed three times with
1 PBS containing 0.1% Triton X-100. They were stained for 1 hr 8823.
10. Choi, J.W., Chen, J., Schreiber, S.L., and Clardy, J. (1996). Struc-with the secondary antibody, FITC-conjugated goat anti-mouse
(1-1000 dilution, Caltag Laboratories), in 1PBS with 2% BSA. Cells ture of the FKBP12-rapamycin complex interacting with the
binding domain of human FRAP. Science 273, 239–242.were washed three times with 1PBS containing 0.1% Triton X-100,
11. Standaert, R.F., Galat, A., Verdine, G.L., and Schreiber, S.L.three times with 1 PBS, and three times with water. They were
(1990). Molecular cloning and overexpression of the humanmounted in Vectashield media containing DAPI (Vector Labora-
FK506-binding protein FKBP. Nature 346, 671–674.tories, Inc.) and photographed using a inverted stage microscope
12. Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T.,equipped with a FITC filter set (Chroma) and a Spot camera.
Lane, W.S., and Schreiber, S.L. (1994). A mammalian proteinFor colocalization experiments, samples were prepared as above
targeted by G1-arresting rapamycin receptor complex. Naturewith the following modifications. To minimize sulfation and conse-
369, 756–758.quent masking of the HA epitope, sodium chlorate (50 mM) was
13. Belshaw, P.J., Ho, S.N., Crabtree, G.R., and Schreiber, S.L.included during the rapamycin incubation. The primary antibody
(1996). Controlling protein association and subcellular localiza-staining utilized mouse anti-HA (3-1000 dilution, Covance Research
tion with a synthetic ligand that induces heterodimerization ofProducts) and a polyclonal rabbit serum against mannosidase II
proteins. Proc. Natl. Acad. Sci. USA 93, 4604–4607.(1-1000 dilution, a gift from Dr. Marilyn Farquhar). During the second-
14. Crabtree, G.R., and Schreiber, S.L. (1996). Three-part inven-ary antibody staining, a Alexa488-conjugated goat anti-rabbit anti-
tions: Intracellular signaling and induced proximity. Trends Bio-body (1-1000 dilution, Molecular Probes) and a Alexa546-conju-
chem. Sci. 21, 418–422.gated goat anti-mouse antibody (1-1000 dilution, Molecular Probes)
15. Clemons, P.A. (1999). Design and discovery of protein dimer-were used. A Leica DMIRB/E inverted microscope equipped with a
izers. Curr. Opin. Chem. Biol. 3, 112–115.xenon arc lamp using a 63 lens was employed for imaging. Image
16. Natsuka, S., Gersten, K.M., Zenita, K., Kannagi, R., and Lowe,stacks containing 20–25 sections spaced 0.3 m apart were ac-
J.B. (1994). Molecular cloning of a cDNA encoding a novel hu-quired using a Quantix CCD camera (Roper Scientific). An 8600
man leukocyte 1,3-fucosyltransferase capable of synthesizingSedat quad filter set with single band excitation and emission filters
the sialyl Lewis X determinant. J. Biol. Chem. 269, 16789–16794.(Chroma) was used, allowing the imaging of DAPI, Alexa488, and
17. Sasaki, K., Kurata, K., Funayama, K., Nagata, M., Watanabe, E.,Alexa546 without any concern for register among the different chan-
Ohta, S., Hanai, N., and Nishi, T. (1994). Expression cloning ofnels. Slidebook software (Intelligent Imaging Solutions) was used
a novel 1,3-fucosyltransferase that is involved in biosynthesisto control the microscope and the camera. The image stacks were
of the sialyl Lewis X carbohydrate determinants in leukocytes.digitally deconvolved using the nearest neighbor algorithm of
J. Biol. Chem. 269, 14730–14737.Slidebook.
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